Form 4: Neurogene Inc. Executive Christine Cvijic Reports Stock and Option Awards
SEC Form 4 Filing
Christine Mikail Cvijic, President and CFO of Neurogene Inc., reports the acquisition of restricted stock units and stock options.
Summary
- On March 26, 2025, Christine Mikail Cvijic, President and CFO of Neurogene Inc., reported transactions involving Neurogene's common stock and employee stock options.
- Cvijic acquired 20,300 restricted stock units (RSUs) that will vest in three equal annual installments starting on the first anniversary of the grant date.
- She also acquired options to purchase 122,000 shares of Neurogene's common stock at an exercise price of $16.14, vesting over four years.
- Following these transactions, Cvijic directly owns 92,643 shares of common stock, which includes 24,000 shares held jointly with her spouse, David Cvijic, and holds options for 122,000 shares.
- The reported transactions were filed with the SEC on March 28, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports routine stock and option grants to an executive. It's a standard practice and doesn't inherently indicate positive or negative performance.
Positives
- The grant of restricted stock units and stock options to the President and CFO aligns her interests with those of the shareholders.
- The vesting schedules for both the RSUs and stock options incentivize continued service and commitment to the company's long-term success.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions reported may have a minor impact on shareholders by slightly diluting the existing shares as the options are exercised in the future.
- Employees may be positively impacted by the incentive structure created by the stock options and restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | Date of the reported transactions: acquisition of restricted stock units and stock options. |
| 03/26/2025 | First vesting date for one-quarter of the acquired stock options. |
| 03/26/2035 | Expiration date of the acquired stock options. |
| 03/28/2025 | Date the Form 4 was signed and filed. |
Keywords
Neurogene Inc., Christine Cvijic, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.